Literature DB >> 17490986

Inclusion of biomarkers for detecting perturbations in the heart and lung and lipid/carbohydrate metabolism in National Toxicology Program studies.

June K Dunnick1, Kristina A Thayer, Gregory S Travlos.   

Abstract

Environmental factors and exposures may contribute to many serious diseases afflicting humans. Biomarkers are useful to understand disease processes and identify early events leading to disease. The National Toxicology Program (NTP) convened a workshop in September 2006 to help identify biomarkers that could be used in toxicology studies with rodents to predict disease outcome and detect early events in disease processes. Expert scientists reviewed biomarkers for disease/injury related to the heart, lung, and/or changes in lipid/carbohydrate metabolism and made recommendations for those that could be incorporated into NTP studies on a routine or selective basis. Although numerous biomarkers were discussed, only a few were considered amenable for routine use. This article summarizes recommendations for the most promising biomarkers and presents the NTP perspective on those that will be included in the bioassay program on a routine or special study basis. Breakout group reports and additional information on the workshop, including participants, presentations, and background materials, are posted on the NTP Web site http://ntp.niehs.nih.gov/go/20940.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490986      PMCID: PMC2080693          DOI: 10.1093/toxsci/kfm113

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  37 in total

Review 1.  Use of bronchoalveolar lavage to detect respiratory tract toxicity of inhaled material.

Authors:  Rogene F Henderson
Journal:  Exp Toxicol Pathol       Date:  2005-07

Review 2.  Biomarkers in acute cardiac disease: the present and the future.

Authors:  Allan S Jaffe; Luciano Babuin; Fred S Apple
Journal:  J Am Coll Cardiol       Date:  2006-06-12       Impact factor: 24.094

Review 3.  Process map proposal for the validation of genomic biomarkers.

Authors:  Federico Goodsaid; Felix Frueh
Journal:  Pharmacogenomics       Date:  2006-07       Impact factor: 2.533

4.  Marginal zinc deficiency exacerbates bone lead accumulation and high dietary zinc attenuates lead accumulation at the expense of bone density in growing rats.

Authors:  Jennifer A Jamieson; Carla G Taylor; Hope A Weiler
Journal:  Toxicol Sci       Date:  2006-04-19       Impact factor: 4.849

5.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Authors:  Emily Lubien; Anthony DeMaria; Padma Krishnaswamy; Paul Clopton; Jen Koon; Radmila Kazanegra; Nancy Gardetto; Erin Wanner; Alan S Maisel
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

6.  Effects of strain and treatment with inhaled aII-trans-retinoic acid on cigarette smoke-induced pulmonary emphysema in mice.

Authors:  Thomas H March; Larry E Bowen; Gregory L Finch; Kristen J Nikula; Bonnie J Wayne; Charles H Hobbs
Journal:  COPD       Date:  2005-09       Impact factor: 2.409

7.  The fructosamine 3-kinase knockout mouse: a tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging.

Authors:  Vincent M Monnier
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

8.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

Authors:  V G De Gruttola; P Clax; D L DeMets; G J Downing; S S Ellenberg; L Friedman; M H Gail; R Prentice; J Wittes; S L Zeger
Journal:  Control Clin Trials       Date:  2001-10

9.  TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.

Authors:  Jose C Florez; Kathleen A Jablonski; Nick Bayley; Toni I Pollin; Paul I W de Bakker; Alan R Shuldiner; William C Knowler; David M Nathan; David Altshuler
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

10.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  V Fonseca; J Rosenstock; R Patwardhan; A Salzman
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.